NDAORALSUSPENSION
Approved
Jul 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
VYSCOXA (celecoxib) by Inpharmus is cyclooxygenase inhibitors [moa]. First approved in 2025.
Drug data last refreshed 5h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VYSCOXA (celecoxib) is an oral COX-2 selective inhibitor approved as a suspension formulation in July 2025. It is a nonsteroidal anti-inflammatory drug (NSAID) used to reduce inflammation and pain, working by inhibiting cyclooxygenase enzymes. The suspension form represents a reformulation of the established celecoxib molecule, likely targeting improved patient convenience or pediatric/elderly populations.
Launch
Early-stage product launch with moderate competitive intensity (30/100), likely supported by a lean but growing commercial team focused on market penetration.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
Started Sep 2024
40 enrolled
Healthy Volunteer
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
Started Jun 2022
59 enrolled
Healthy Volunteers
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
Started Jun 2022
25 enrolled
Colorectal Cancer
Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
Started Jan 2019
53 enrolled
Malignant Pleural Mesothelioma
Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.
Started Mar 2017
637 enrolled
Acute Post-surgical Pain
Worked on VYSCOXA at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.